Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
5Annual filing director officer or owner of more than ten percent.Feb 14, 2018View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 14, 2018View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 14, 2018View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 14, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 13, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 12, 2018View HTMLDownload DOCDownload PDFDownload XLS
CT ORDERConfidential treatment orderFeb 12, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 8, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesFeb 5, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 5, 2018View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GJan 26, 2018View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJan 9, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 4, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 4, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJan 2, 2018View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesDec 18, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesDec 4, 2017View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventNov 28, 2017View HTMLDownload DOCDownload PDFDownload XLS
CT ORDERConfidential treatment orderNov 17, 2017View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-100      101-125      126-146

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information